FAQ

CI 1040

Known as: CI-1040, CI1040 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2018
051020022018

Related topics

Related topics

1 relation
PD 184352

Related mentions per year

Related mentions per year

2000-2018
20002005201020152020
CI 1040
PD 184352

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
Though prostate cancer (PCa) has slow progression, the hormone refractory (HRCP) and metastatic entities are substantially lethal… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlotinib is limited by the development of drug… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK.
OBJECTIVE Abdominal aortic aneurysm (AAA) is a life-threatening disease affecting almost 10% of the population over age 65… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?
2008
2008
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2007
2007
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
CONTEXT Targeting MAPK kinase (MEK) in the MAPK pathway is a potentially effective therapeutic strategy for thyroid cancer… (More)
Is this relevant?
2006
2006
The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder that results in neuroectodermal tumors. The NF1 tumor… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
PURPOSE This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD… (More)
Is this relevant?
2005
2005
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
PURPOSE This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral… (More)
Is this relevant?